Dynamic population pharmacokinetic–pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice‐daily dosing of canagliflozin

AIM: Canagliflozin is an SGLT2 inhibitor approved for the treatment of type‐2 diabetes. A dynamic population pharmacokinetic–pharmacodynamic (PK/PD) model relating 24‐h canagliflozin exposure profiles to effects on glycosylated haemoglobin was developed to compare the efficacy of once‐daily and twic...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Br J Clin Pharmacol
Huvudupphovsmän: de Winter, Willem, Dunne, Adrian, de Trixhe, Xavier Woot, Devineni, Damayanthi, Hsu, Chyi‐Hung, Pinheiro, Jose, Polidori, David
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2017
Ämnen:
Pharmacokinetic Dynamic Relationships
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5401970/
https://ncbi.nlm.nih.gov/pubmed/28138980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13180
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk